eflapegrastim-xnst injection
for subcutaneous use Initial U.S. Approval: 2022

Rolvedon (eflapegrastim-xnst) is a leukocyte growth factor used to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. FDA-approved use: To decrease the incidence of infection in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia

Facts about eflapegrastim-xnst injection

Approval Date: 9/9/2022
Proprietary Name: Rolvedon
Active Ingredient(s): eflapegrastim-xnst
Dosage Form: Injection
DISEASE INDICATIONS-Breast Cancer, Lung Cancer
MANUFACTURER-Spectrum Pharmaceuticals, Inc.
USAGE-Intravenous
MEDICINE APPROVED BY-Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “eflapegrastim-xnst injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.